Journal
GUT
Volume 63, Issue 6, Pages 974-983Publisher
BMJ PUBLISHING GROUP
DOI: 10.1136/gutjnl-2013-305559
Keywords
-
Categories
Funding
- University of Cambridge
- Cancer Research UK
- Li Ka Shing Foundation
- Hutchison Whampoa Limited
- National Institute for Health Research Cambridge Biomedical Research Centre
- European Community [EPC-TM-Net 256974]
- Deutsche Krebshilfe Mildred Scheel Postdoctoral Fellowship
- Lustgarten Foundation for Pancreatic Cancer Research
- Cold Spring Harbor Laboratory Association
- Cancer Research UK [15678, 22310] Funding Source: researchfish
Ask authors/readers for more resources
Design Pharmacokinetic and pharmacodynamic parameters of cremophor-paclitaxel, nab-paclitaxel (human-albumin-bound paclitaxel, Abraxane) and a novel mouse-albumin-bound paclitaxel (m-nab-paclitaxel) were evaluated in genetically engineered mouse models (GEMMs) by liquid chromatography-tandem mass spectrometry (LC-MS/MS), histological and biochemical analysis. Preclinical evaluation of m-nab-paclitaxel included assessment by three-dimensional high-resolution ultrasound and molecular analysis in a novel secreted protein acidic and rich in cysteine (SPARC)deficient GEMM of pancreatic ductal adenocarcinoma (PDA). Results nab-Paclitaxel exerted its antitumoural effects in a dose-dependent manner and was associated with less toxicity compared with cremophor-paclitaxel. SPARC nullizygosity in a GEMM of PDA, Kras(G12D); p53(flox/-); p48Cre (KPfC), resulted in desmoplastic ductal pancreas tumours with impaired collagen maturation. Paclitaxel concentrations were significantly decreased in SPARC null plasma samples and tissues when administered as low-dose m-nab-paclitaxel. At the maximally tolerated dose, SPARC deficiency did not affect the intratumoural paclitaxel concentration, stromal deposition and the immediate therapeutic response. Conclusions nab-Paclitaxel accumulates and acts in a dose-dependent manner. The interaction of plasma SPARC and albumin-bound drugs is observed at low doses of nab-paclitaxel but is saturated at therapeutic doses in murine tumours. Thus, this study provides important information for future preclinical and clinical trials in PDA using nab-paclitaxel in combination with novel experimental and targeted agents.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available